Your trusted source for investing success

Tag: short term investments

Hecla Reports First Quarter 2017 Results

Hecla Mining (NYSE:HL) (Hecla or the Company) today announced first quarter financial and operating results.

First Quarter 2017 Highlights:

Net income applicable to common stockholders of $26.7 million, or $0.07 per basic share.
Adjusted net income applicable to common stockholders of $16.7 million, or $0.04 per basic share.
Sales of $142.5

Hecla Reports 3.4 Million Ounces of Silver and 56,113 Ounces of Gold Production

Cash and Cash-Like Investments Now $213 Million; a $14 Million Increase Over Year-End
Hecla Mining Company (NYSE:HL) today announced preliminary production, operating costs and cash balance for the first quarter of 2017.

First Quarter 2017 Highlights (Preliminary Results)

Silver production of 3.4 million ounces; gold production of 56,113 ounces.
Silver equivalent production

Canadian Zinc Reports Financial Results for 2016

Canadian Zinc Corporation (TSX: CZN; OTCQB: CZICF) (“the Company” or “Canadian Zinc”) reports its financial results for the year ended December 31, 2016.

As quoted in the press release:
For the year ended December 31, 2016, Canadian Zinc reported a net loss and comprehensive loss of $5,077,000 compared to a net loss

Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver Fibrosis

NEW YORK, Feb. 10, 2017 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will provide an update on the Phase 3 REGENERATE trial of obeticholic acid (OCA) in NASH patients with liver fibrosis

Enter Your Log In Credentials

Privacy & Legal Policy

Privacy Policy

Investing News Network